189 related articles for article (PubMed ID: 34601284)
1. Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer.
Onuma T; Mizutani T; Fujita Y; Yamada S; Yoshida Y
J Trace Elem Med Biol; 2021 Dec; 68():126865. PubMed ID: 34601284
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
3. Secretion of vascular endothelial growth factor in ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Cannon MJ; Pecorelli S; Parham GP
Eur J Gynaecol Oncol; 1999; 20(3):177-81. PubMed ID: 10410879
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic protein expression in advanced epithelial ovarian cancer.
Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of trace elements associated with antioxidant enzymes in blood of primary epithelial ovarian cancer patients.
Caglayan A; Katlan DC; Tuncer ZS; Yüce K
J Trace Elem Med Biol; 2019 Mar; 52():254-262. PubMed ID: 30732891
[TBL] [Abstract][Full Text] [Related]
6. Trace elements analysis of ascitic fluid in benign and malignant diseases.
Celik HA; Aydin HH; Ozsaran A; Kilincsoy N; Batur Y; Ersoz B
Clin Biochem; 2002 Sep; 35(6):477-81. PubMed ID: 12413609
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
8. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.
Boocock CA; Charnock-Jones DS; Sharkey AM; McLaren J; Barker PJ; Wright KA; Twentyman PR; Smith SK
J Natl Cancer Inst; 1995 Apr; 87(7):506-16. PubMed ID: 7707437
[TBL] [Abstract][Full Text] [Related]
9. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
11. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Candido Dos Reis F; Moreira de Andrade J; Bighetti S
Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
[TBL] [Abstract][Full Text] [Related]
12. PDGF BB induces VEGF secretion in ovarian cancer.
Matei D; Kelich S; Cao L; Menning N; Emerson RE; Rao J; Jeng MH; Sledge GW
Cancer Biol Ther; 2007 Dec; 6(12):1951-9. PubMed ID: 18075302
[TBL] [Abstract][Full Text] [Related]
13. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
[TBL] [Abstract][Full Text] [Related]
14. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
15. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
[TBL] [Abstract][Full Text] [Related]
17. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.
Yeo KT; Wang HH; Nagy JA; Sioussat TM; Ledbetter SR; Hoogewerf AJ; Zhou Y; Masse EM; Senger DR; Dvorak HF
Cancer Res; 1993 Jun; 53(12):2912-8. PubMed ID: 8504432
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin is detectable in the ascitic fluid in patients with ovarian tumors.
Stefanovic V; Pakarinen P; Alfthan H; Stenman UH; Leminen A; Pociuviene J; Riska A; Loukovaara M
Int J Gynecol Cancer; 2012 Nov; 22(9):1470-3. PubMed ID: 23027039
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; Boonstra H; Sweep CG
Cancer; 2001 Jan; 91(2):371-7. PubMed ID: 11180084
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.
Rudlowski C; Pickart AK; Fuhljahn C; Friepoertner T; Schlehe B; Biesterfeld S; Schroeder W
Int J Gynecol Cancer; 2006; 16 Suppl 1():183-9. PubMed ID: 16515588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
